Cutaneous Melanoma
74
26
37
18
Key Insights
Highlights
Success Rate
58% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
17.6%
13 terminated out of 74 trials
58.1%
-28.5% vs benchmark
3%
2 trials in Phase 3/4
50%
9 of 18 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 18 completed trials
Clinical Trials (74)
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)
Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint Inhibitors
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
Exercise to Boost Response to Checkpoint Blockade Immunotherapy